1. Immune and behavioral correlates of protection against symptomatic post-vaccination SARS-CoV-2 infection.
- Author
-
Goguet E, Olsen CH, Meyer WA 3rd, Ansari S, Powers JH 3rd, Conner TL, Coggins SA, Wang W, Wang R, Illinik L, Sanchez Edwards M, Jackson-Thompson BM, Hollis-Perry M, Wang G, Alcorta Y, Wong MA, Saunders D, Mohammed R, Balogun B, Kobi P, Kosh L, Bishop-Lilly K, Cer RZ, Arnold CE, Voegtly LJ, Fitzpatrick M, Luquette AE, Malagon F, Ortega O, Parmelee E, Davies J, Lindrose AR, Haines-Hull H, Moser MS, Samuels EC, Rekedal MS, Graydon EK, Malloy AMW, Tribble DR, Burgess TH, Campbell W, Robinson S, Broder CC, O'Connell RJ, Weiss CD, Pollett S, Laing ED, and Mitre E
- Subjects
- Adult, Humans, SARS-CoV-2, COVID-19 Vaccines, Antibodies, Viral, Immunoglobulin G, COVID-19 prevention & control
- Abstract
Introduction: We sought to determine pre-infection correlates of protection against SARS-CoV-2 post-vaccine inzfections (PVI) acquired during the first Omicron wave in the United States., Methods: Serum and saliva samples from 176 vaccinated adults were collected from October to December of 2021, immediately before the Omicron wave, and assessed for SARS-CoV-2 Spike-specific IgG and IgA binding antibodies (bAb). Sera were also assessed for bAb using commercial assays, and for neutralization activity against several SARS-CoV-2 variants. PVI duration and severity, as well as risk and precautionary behaviors, were assessed by questionnaires., Results: Serum anti-Spike IgG levels assessed by research assay, neutralization titers against Omicron subvariants, and low home risk scores correlated with protection against PVIs after multivariable regression analysis. Commercial assays did not perform as well as research assay, likely due to their lower dynamic range., Discussion: In the 32 participants that developed PVI, anti-Spike IgG bAbs correlated with lower disease severity and shorter duration of illness., Competing Interests: SP, TB, and DT report that the USU IDCRP, a U.S. Department of Defense DoD Institution, and the HJF were funded under a Cooperative Research and Development Agreement to conduct an unrelated phase III COVID-19 monoclonal antibody immunoprophylaxis trial sponsored by AstraZeneca. The HJF, in support of the USU IDCRP, was funded by the DoD Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense to augment the conduct of an unrelated phase III vaccine trial sponsored by AstraZeneca. Both trials were part of the USG COVID-19 response. Neither is related to the work presented here. Authors WM and SA were employed by the company Quest Diagnostics. Author JP was employed by company Leidos Biomedical Research, Inc. Authors LV, MF, AL and FM were employed by company Leidos. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Goguet, Olsen, Meyer, Ansari, Powers, Conner, Coggins, Wang, Wang, Illinik, Sanchez Edwards, Jackson-Thompson, Hollis-Perry, Wang, Alcorta, Wong, Saunders, Mohammed, Balogun, Kobi, Kosh, Bishop-Lilly, Cer, Arnold, Voegtly, Fitzpatrick, Luquette, Malagon, Ortega, Parmelee, Davies, Lindrose, Haines-Hull, Moser, Samuels, Rekedal, Graydon, Malloy, Tribble, Burgess, Campbell, Robinson, Broder, O’Connell, Weiss, Pollett, Laing and Mitre.)
- Published
- 2024
- Full Text
- View/download PDF